Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

Vanessa Caceres  |  Issue: October 2017  |  October 17, 2017

Right: The small molecule structure of aspirin (21 molecules). Left: A monoclonal antibody made up of 10,000–20,000 molecules.

Right: The small molecule structure of aspirin (21 molecules). Left: A monoclonal antibody made up of 10,000–20,000 molecules.
DNA Illustrations / Science Source

As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market.

The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the European Commission.1 Highlights:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Biosimilars have been in the European Union (EU) since 2006, and the EU has approved the highest number of biosimilars worldwide.
  • The EU monitoring system for safety concerns has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines since their approval.
  • Although biosimilars may have minor differences from their reference medicines, these differences are not clinically meaningful. There are no expected differences in safety and efficacy.
  • Biosimilars in the EU have been approved using the same standards of pharmaceutical quality, safety and efficacy as those of all biological medicines.
  • A biosimilar can rely on the safety and efficacy gained during research with the reference medicine. This means clinical trials are not needed for each indication for which the biosimilar seeks approval.
  • Because an approved biosimilar is very similar to its reference medicine and has the expected comparable safety and efficacy in one therapeutic indication, data can be extrapolated to other indications for which the reference medicine has been approved. “Extrapolation needs to be supported by all the scientific evidence generated in comparability studies,” according to the report.
  • Biosimilar competition offers benefits to EU healthcare systems because it can improve patient access to safe and effective medicines with proved quality.

The findings from the report demonstrate Europe’s 10-year head start compared with the U.S. market, says Angus B. Worthing, MD, FACP, FACR, Arthritis & Rheumatism Associates, in the Washington, D.C., area, and chair of the ACR’s Government Affairs Committee. “Biosimilars were first approved in Europe more than 10 years ago and with more than 25 drugs in use, none has been pulled for safety problems. Pharmacovigilance programs have not identified any safety issues in biosimilars that differed from reference drugs,” he says.

This broad experience contrasts with that in the U.S., which has just six biosimilars approved by the U.S. Food and Drug Administration (FDA) (see Table 1).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug Updates Tagged with:AC&Radverse eventsAmerican College of Rheumatology (ACR)BiosimilarsBiosimilars in the EUdrugefficacyEuropeEuropean UnionfindingsinterchangeabilityMedicationoutcomepatient carepricingreportRheumatic DiseaserheumatologistsrheumatologySafetyTreatment

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences